What is ImmunityBio?
ImmunityBio is dedicated to creating advanced immunotherapies and cell therapies designed to activate and sustain an immune response, offering durable and safe protection against a spectrum of diseases. The company's flagship product, ANKTIVA, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer with CIS, known for its ability to activate natural killer cells, T cells, and memory T cells for prolonged responses. ImmunityBio is strategically applying its scientific expertise to develop novel cancer vaccines and immunotherapies, aiming to reduce or eliminate the reliance on traditional high-dose chemotherapy. Their platforms are engineered for enhanced efficacy, accessibility, and ease of administration in oncology and infectious disease treatment.
How much funding has ImmunityBio raised?
ImmunityBio has raised a total of $1.2B across 7 funding rounds:
Other Financing Round
$470M
Debt
$157M
Private Equity
$50M
Share Placement
$40M
Other Financing Round
$320M
Share Placement
$75M
Other Financing Round
$75M
Other Financing Round (2021): $470M with participation from Dr. Patrick Soon-Shiong and NantCapital
Debt (2022): $157M, investors not publicly disclosed
Private Equity (2023): $50M, investors not publicly disclosed
Share Placement (2023): $40M, investors not publicly disclosed
Other Financing Round (2024): $320M backed by Oberland Capital
Share Placement (2025): $75M, investors not publicly disclosed
Other Financing Round (2026): $75M led by Oberland Capital
Key Investors in ImmunityBio
Dr. Patrick Soon-Shiong
Dr. Patrick Soon-Shiong is a prominent figure in biotechnology and healthcare, known for his entrepreneurial ventures and significant investments in life sciences. His involvement suggests a deep commitment to advancing innovative medical technologies and therapies.
NantCapital
NantCapital is an investment firm likely associated with Dr. Patrick Soon-Shiong, focusing on strategic investments in biotechnology and healthcare companies. Their backing indicates confidence in ImmunityBio's scientific approach and market potential.
Oberland Capital
Oberland Capital is a private investment firm specializing in funding innovation within the global healthcare industry. They provide flexible financing solutions, including significant capital investments, to accelerate the development and commercialization of healthcare products.
What's next for ImmunityBio?
The recent major strategic investment positions ImmunityBio for accelerated growth and the expansion of its clinical pipeline. With a focus on developing potentially curative cancer vaccines and advanced immunotherapies, the company is poised to address significant unmet needs in oncology and infectious diseases. The enterprise-level capital infusion will likely support further research and development, clinical trial progression, and the scaling of manufacturing capabilities. ImmunityBio's commitment to innovation, underscored by its FDA-approved ANKTIVA, suggests a strategic trajectory focused on transforming standards of care and delivering impactful therapeutic solutions.
See full ImmunityBio company page
